Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Minerva Biotechnology
Minerva Biotechnologies Announces Major Breakthrough on New Cancer Therapy Target MUC1*
May 13th, 2008
Minerva Biotechnology, a leading nanotechnology, cancer and stem cell development company announced a major breakthrough in a cancer target that is widely expressed in human cancers. Minerva used its proprietary nanoparticle technology to elucidate a key molecular mechanism that is involved in cancer cell growth and metastasis. The study, published in the journal PLoS ONE focuses on a cell surface receptor, called MUC1, which according to extensive scientific literature is aberrantly expressed on 75% of all human solid tumors - 96% of breast cancers, 47% of prostate cancers, as well as high percentages of ovarian, colorectal, non-small cell lung,...
Source: Cancer Weekly (2008-05-13)
|
